Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | DRD4 | P21917 | 5/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 5/20 | 0.61 |
| ▸ | DRD3 | P35462 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28537686 | 0.97 | CCR3 (0.94) | CCR3OPRL1POLBDRD4OPRM1 | |
| SCHEMBL8891476 | 0.94 | CCR3 (0.89) | CCR3OPRL1POLBDRD4OPRM1 | |
| SCHEMBL28525891 | 0.94 | CCR3 (0.89) | CCR3OPRL1POLBDRD4OPRM1 | |
| SCHEMBL29087358 | 0.91 | CCR3 (0.83) | CCR3OPRL1POLBDRD4OPRM1 | |
| SCHEMBL1411499 | 0.90 | OPRL1 (1.00) | CCR3OPRL1POLBDRD4OPRM1 | |
| SCHEMBL3890625 | 0.88 | OPRL1 (0.82) | CCR3OPRL1POLBDRD4SIGMAR1 | |
| SCHEMBL27582059 | 0.87 | CCR3 (0.82) | CCR3OPRL1POLBOPRM1SIGMAR1 | |
| SCHEMBL6496650 | 0.86 | CCR3 (0.74) | CCR3OPRL1POLBDRD4OPRM1 | |
| SCHEMBL8891162 | 0.86 | CCR3 (0.76) | CCR3OPRL1POLBDRD4SIGMAR1 | |
| SCHEMBL3898508 | 0.86 | OPRL1 (0.79) | CCR3OPRL1POLBDRD4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118125969-A | Haloperidol with excellent biological performance and preparation method and application thereof | 湖南洞庭药业股份有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-113122050-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-112538042-A | Preparation method of haloperidol | 湖南洞庭药业股份有限公司 | 2021-03-23 | — | — | CN | claimed |
| CN-118125969-A | Haloperidol with excellent biological performance and preparation method and application thereof | 湖南洞庭药业股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-113122050-B | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-113122050-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-112538042-A | Preparation method of haloperidol | 湖南洞庭药业股份有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-3096754-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020161005-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020119973-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| EP-1204664-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1204640-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1202985-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Millennium Pharmaceuticals, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001009094-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009137-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009119-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119973-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | CCL11, ACKR3, CXCR4 | CCR3 19/4885OPRL1 139/4885POLB 2278/4885 |
| US-20020161005-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | CCL11, ACKR3, CXCR4 | CCR3 19/4885OPRL1 137/4885POLB 2377/4885 |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | NFATC1, ELANE, NCF1 | CCR3 16/4885OPRL1 585/4885POLB 1826/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CCR3 12/4885OPRL1 106/4885POLB 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.